Author

C. Gorrini

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

A. Bellini· 1 shared A. Carcaboso· 1 shared A. Goodman· 1 shared A. Saint-Charles· 1 shared B. Geoerger· 1 shared B. Martins da Costa· 1 shared C. Hutchinson· 1 shared C. Pierre-Eugene· 1 shared

Activity by Year

2023-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Bellini

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

COMBINATION THERAPIES TARGETING ALK-ABERRANT NEUROBLASTOMA IN PRECLINICAL MODELS.

E. Tucker, I. Jimenez, L. Chen, A. Bellini, C. Gorrini, E. Calton, Q. Gao, H. Che, E. Poon, Y. Jamin, B. Martins da Costa, K. Barker, S. Shrestha, C. Hutchinson, S. Dhariwal, , G. Schleiermacher

This study evaluates lorlatinib, an ALK inhibitor, in combination with chemotherapy or idasanutlin in preclinical neuroblastoma models, finding synergy in models with high ALK expression.

Clinical Cancer Research · Apr 3, 2023Peer-reviewedCancer Biology